Ankit Rao

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

Ipilimumab in the real world

Saif Ahmad, Wendi Qian, Sarah Ellis et al. · Melanoma Research · 2015 · 52 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study

Edmond Atallah, Sarah J. Welsh, Brent O’Carrigan et al. · JHEP Reports · 2023 · 52 citations · Full text

Pharmacy, Oncology, Cancer Epidemiology +14

A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)

Alimu Dayimu, Avinash Gupta, Rubeta Matin et al. · European Journal of Cancer · 2023 · 12 citations · Full text

Medicine, Oncology, Pharmacology +13